Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Medivation Shares Almost Double in Early Trading on Drug Results

Nov. 3 (Bloomberg) -- Medivation Inc. almost doubled in early trading after saying that a trial of the company’s prostate cancer drug has been halted and the medicine will be given to all participants.

Medivation surged to $32 at 7:33 a.m. The trial’s monitoring committee made the recommendation after seeing interim results, the San Francisco-based company and partner Astellas Pharma Inc. said in a statement today.

Link to Company News:{4503 JP <Equity> CN <GO>} Link to Company News:{MDVN US <Equity> CN <GO>}

To contact the reporter on this story: Bruce Rule in New York at

To contact the editor responsible for this story: Bruce Rule at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.